key: cord-0268036-pf2nnhuc authors: Sarkar, S.; das, S.; Choudhury, K.; Mukherjee, S.; Chatterjee, R. title: Seroprevalence and Dynamics of anti-SARS-CoV-2 antibody among healthcare workers following ChAdOx1 nCoV-19 vaccination date: 2021-07-22 journal: nan DOI: 10.1101/2021.07.20.21260278 sha: 64a1df58e162bc580ac0abafa11115b9ce9e9eff doc_id: 268036 cord_uid: pf2nnhuc Abstract Background The serological evaluations of IgG, IgM, and IgA to the SARS-CoV-2 proteins are widely used for the epidemiological assessment of COVID-19. The Health Care Workers (HCWs) are presumably exposed to a higher risk of acquiring the disease owing to their regular contact with the patients. Methods COVID-19 prevalence was investigated by classifying 313 HCWs into four groups based on their degree of exposure and estimating the IgG and total antibody. The serological assessment of the anti-SARS-CoV-2 antibody was conducted 21 days post-vaccination of first or both doses of the ChAdOx1 nCoV-19 vaccine among 174 HCWs. The vaccinated HCWs were followed up for 3 months for SARS-CoV-2 infection. Findings The levels of anti-SARS-CoV-2 IgG were comparable among different groups, but the seroprevalence gradually decreased from the most exposed to the less exposed group. The neutralizing antibody was positively correlated with IgG as well as total antibody. IgG was marginally decreased after 2 months followed by a significant drop after 4-6 months post-infection. However, 80% of the HCWs developed a detectable amount of IgG after the first dose of vaccination, the median titer of which was comparable to the seropositive HCWs after natural infection. Almost 100% of the HCWs developed antibodies after the second dose of vaccine with boosting effect among the seropositive HCWs. Although ~11.5% of the vaccinated HCWs were infected with the SARS-CoV-2, ~94% of them showed mild symptoms and recovered in home isolation without any O2 support. Interpretations The varying level of seroprevalence among the four groups suggested a stratified spread of the disease. One dose of SARS-CoV-2 vaccination was found to be effective in terms of the antibody titer, while the second dose was required to cover the larger population. The effectiveness of the ChAdOx1 nCoV-19 vaccine was noticeable due to the low rate of post-vaccination infection with moderate or severe symptoms. Coronavirus disease 2019 (COVID-19) started as a regional epidemic in December 2019 in Wuhan, China, but 2 its rapid expansion made it a global pandemic affecting almost all the countries and significant mortality 1,2 . 3 While every affected country has taken containment and mitigation measures, the spread of COVID-19 is still 4 prominent 3 . The spectrum of clinical syndromes caused by SARS-CoV-2 ranges from asymptomatic cases to 5 mild flu-like symptoms to severe pneumonia, acute respiratory distress syndrome (ARDS) and death. Many 6 experts believe that unnoticed, asymptomatic cases of coronavirus infection could be the hidden source of 7 contagion 4-7 . The Health care workers (HCW) are the frontline workforce for clinical care and are presumably 8 exposed to a higher risk of acquiring the disease than the general population. If infected, they not only pose a 9 risk to the vulnerable patients and the fellow HCW 8-10 but associated morbidity and mental stress also cause 10 disruption of patient care 11 . After primary infection, IgG antibody production can be maintained for a long time in any viral infection 12 Although there is evidence on the immunological responses against SARS-CoV-2, but the time to 24 seroconversion and the antibody levels elicited in relation to the patient profile are not fully characterized yet. 25 Importantly, the correlation between seropositivity or antibody levels and protection against re-infection, as well 26 as the duration of protective immunity, remains to be elucidated. The present study highlights several key aspects of antibody generation among HCWs in a tertiary care hospital 28 of Kolkata. We determined the overall infection prevalence (past and current) to SARS-CoV-2, the prevalence 29 of asymptomatic infections, SARS-CoV-2 antibody kinetics and longevity as well as the development of The study population were chosen randomly irrespective of their working department and divided into 4 groups 46 (A, B, C and D) based on their working area, direct care to COVID-19 patient, face-to-face contact (within 1 47 meter) and duration of exposure to the COVID patients, performed any aerosol-generating procedures or direct 48 contact with the environment where the confirmed COVID-19 patient was cared like bed, linen, medical 49 equipment, bathroom etc. 17 . Individuals within Group A were the most exposed and Group D were the least. HCWs with 5 hours of cumulative exposure per day to the covid patient directly or indirectly were included in 51 Group A. Those HCWs with 4hrs, 3hrs and 1hr cumulative exposure per day to the COVID-19 patient were 52 included in Group B, Group C and Group D, respectively. Participants with symptoms suggestive of recent 53 infection or positive RT-PCR test result within last 14 days were excluded from the study. A structured 54 questionnaire comprising demographics, prior symptoms with their duration, prior COVID-19 test results, 55 working location (in terms of working in COVID or Non-COVID unit), co-morbidities were collected prior to 56 the blood collection for SARS-CoV-2 antibody testing. 57 All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. Descriptive as well as inferential analyses were performed using R Software 21 . A significance level of p ≤ 0.01 31 was considered unless it was specifically mentioned. The mean age of the 313 HCWs was 37.83 (SD=12.31) with 54% male and 46% female. Around 51% of them 34 were involved in direct care of the COVID-19 patients with different level of exposures. Based on their 35 occupational risks and degree of exposures, HCWs were classified into four groups. The mean ages of all four 36 groups were also approximately similar. Besides their co-morbidities, COVID-19 like symptoms, working in 37 COVID unit and use of prophylactic drug was also recorded for each subject (Table 1) . Around 34% (106) of the HCWs were seropositive for IgG while 40% (126) of them were seropositive for total 40 antibody (IgG, IgM and IgA). The median IgG titer (signal to cut-off ratio, henceforth referred as S/Co ratio) 41 was 6.30 with median absolute deviation (MAD) was 3.27 for IgG reactive individuals. Whereas the median 42 total antibody titer was 141 S/Co ratio (MAD=101.60) among seroreactive HCWs. Seroprevalence was not 43 significantly different with respect to age or sex of the HCWs (p-value=0.4798, OR=1.18, 95% CI=0.74-1.88). Although the median IgG titer were comparable for four groups (median S/Co ratio for Group A = 5. Figure 1C ). Around 35% HCWs, who 53 All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted July 22, 2021. ; https://doi.org/10.1101/2021.07.20.21260278 doi: medRxiv preprint worked in the COVID-19 unit were seropositive. A similar proportion of seropositive HCWs were also observed 1 in non-COVID unit HCWs (p-value=0.9154, OR=1.08, 95% CI=0.64-1.63). Following ICMR guidelines 22 , 2 HCWs were advised to consume hydroxychloroquine (HCQ) as a prophylactic medication. In our entire study 3 population only 27% have consumed HCQ as prophylaxis. The seropositivity among HCQ consumer and non-4 consumer was not significantly different (p-value=0.3285, OR=0.776, 95% CI=0.44-1.30) ( Table 2) . As 5 consumption of HCQ did not significantly affect the entire population, we didn't pursue it for further analysis on 6 group wise effect of HCQ. 7 Next, we wanted to evaluate the IgG prevalence among symptomatic and asymptomatic HCWs. Around 38% of 8 the studied population developed at least one of the COVID-19 symptoms in recent past. We identified 24% of 9 the asymptomatic HCWs developed IgG, whereas 52% of the symptomatic individuals were found to be 10 seropositive for SARS-CoV-2 antibody (OR=3.49, 95% CI=2.14-5.70, p-value=3.5×10 -7 ) ( Figure 1D ). We 11 further evaluated the association of seropositivity among different COVID-19 suggestive symptoms, and found 12 a significant association with all symptoms, among which fever and headache showed higher significance 13 compared to other symptoms (OR=3.397, 95% CI=2.05-5.62, p-value=1.179×10 -6 ) ( (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted July 22, 2021. As HCWs are the most exposed to SARS-CoV-2 infection, determination of seroprevalence among different 28 working groups is an effective indicator to monitor and control the spread of SARS-CoV-2 infection. Seroprevalence rate was found to be different among HCWs in several countries due to various factors like 30 selection bias in recruiting study participants, study period, awareness and effective implementation of infection 31 control practices, adequate use of PPE, maintenance of hand hygiene and physical distance, early identification 32 and timely isolation and quarantine as well as seroprevalence rate in the community 24-28 . In this study, the seropositivity among HCWs in a tertiary care hospital was 34% for IgG during November 34 2020 to January 2021, which was similar to a study conducted during April 2020 among the HCWs at a tertiary 35 hospital in New York city, USA (36%) 29 . It was observed that the seroprevalence among HCWs in this study 36 was higher to the reported seroprevalence of 26% among the HCWs in Kolkata during September 2020 28 . The 37 third pan India serosurvey, conducted during December 2020-January 2021 also reported 25.6% seroprevalence 38 among the HCWs in India 30 , suggesting variable seroprevalence among the HCWs across different parts of the 39 country. In contrary to our observation, the pan India serosurvey did not identify any difference in 40 seroprevalence between different HCW categories. This difference might be due to inadequate stratification of 41 risk groups among the HCWs. However, variable prevalence among HCWs across different parts of the country 42 might also impact the results of their study. The overall seroprevalence data showed no significant association with age or sex, as also was observed in 44 second and third pan India serosurvey conducted in August and December 2020 30, 31 . As Group A and Group B 45 were mostly exposed to COVID-19 patients, seropositivity of these two groups was similar, whereas Group C 46 and Group D showed significantly low seropositivity compared to groups A and B. The decreasing trend of 47 seroprevalence ranging from 54% to 23% from high risk to low-risk group for both IgG and total antibody 48 vividly portrayed the association of seroprevalence with SARS-CoV-2 infection risk. The total antibody titer 49 (S/Co ratio) was significantly higher than IgG because it includes IgA, IgM along with IgG. Among the IgG 50 non-reactive individuals, 10% showed presence of detectable amount of total anti-SARS-CoV-2 antibody, 51 suggesting presence of only IgA and IgM. The pan India serosurvey also reported variable seroprevalence in 52 urban and rural areas with higher prevalence in urban slum areas than rural areas 31 . Working in COVID-19 or non-COVID-19 unit was not associated with increased antibody positivity in HCWs. The seroprevalence study from Spanish hospital also found no association of COVID-19 with working in 55 COVID unit suggesting that awareness and strict adherence to infection control protocols were sufficient to 56 prevent transmission to HCWs 25 . 57 All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. This study also evaluated the effect of HCQ as prophylaxis for COVID-19 in terms of seroprevalence among the 1 HCQ consumers and non-consumers. In a hospital based seroprevalence study in Kolkata, there was a 2 significant association of seroreactivity with adequate HCQ consumption as only 1.3% of HCQ consumers 3 became reactive 28 . But in this study, we did not find any effect of HCQ prophylaxis on seroprevalence of 4 COVID-19. We know that the cellular immune response plays an important role to clear the virus from host cell and humoral 6 immune response is responsible for preventing future infection. Although the plaque reduction neutralization 7 test (PRNT) is the gold standard for neutralization assays, it is cumbersome, time consuming and require 8 Biosafety Level 3 facilities. Therefore, we performed ELISA based neutralizing assay to substantiate the 9 preventive immunity of anti-spike IgG and found 100% of seropositive individuals developed detectable (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted July 22, 2021. ; https://doi.org/10.1101/2021.07.20.21260278 doi: medRxiv preprint comprehensive study over the general population following vaccination will be necessary to monitor the trend 1 and optimal resource utilization for better management of the ongoing pandemic in a large country like India. 58 All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted July 22, 2021. ; https://doi.org/10.1101/2021.07.20.21260278 doi: medRxiv preprint All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted July 22, 2021. ; https://doi.org/10.1101/2021.07.20.21260278 doi: medRxiv preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted July 22, 2021. ; https://doi.org/10.1101/2021.07.20.21260278 doi: medRxiv preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted July 22, 2021. All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted July 22, 2021. ; https://doi.org/10.1101/2021.07.20.21260278 doi: medRxiv preprint WHO Declares COVID-19 a Pandemic COVID-19 and globalization Public health measures to slow community spread of COVID-19 Clinical characteristics of coronavirus disease 2019 (COVID-19) in 21 China: A systematic review and meta-analysis Clinical Characteristics of Patients Who Died of Coronavirus 23 Disease 2019 in China Clinical characteristics and imaging manifestations of the 2019 novel 25 coronavirus disease (COVID-19):A multi-center study in Wenzhou city Clinical Characteristics of Coronavirus Disease 2019 in China COVID-19 and the Risk to Health Care Workers: A Case Report The COVID-19 pandemic: major risks to healthcare and other workers on the front line Covid-19: risks to healthcare workers and their families Doctors and healthcare workers at frontline of COVID 19 epidemic: Admiration, a pat on the 36 back, and need for extreme caution Duration of humoral immunity to common viral and vaccine 38 antigens Serologic responses to SARS-CoV-2 infection among hospital 40 staff with mild disease in eastern France PM to launch Pan India Rollout of COVID-19 Vaccination drive on 16 Characterization of the Second Wave of COVID-19 in India Antibody Status and Incidence of SARS-CoV-2 Infection 1 in Health Care Workers Seroprevalence of antibodies against SARS SARS-CoV-2 exposure, symptoms and seroprevalence in 5 healthcare workers in Sweden Association of SARS-CoV-2 Seropositive Antibody Test With Risk of Future Infection Seroprevalence of COVID-19 Amongst Health Care 9 Workers in a Tertiary Care Hospital of a Metropolitan City from India Antibodies Among Healthcare Workers at a Tertiary Academic Hospital in New York City SARS-CoV-2 seroprevalence among the general 15 population and healthcare workers in India SARS-CoV-2 antibody seroprevalence in India findings from the second nationwide household serosurvey Robust neutralizing antibodies to SARS-CoV-2 infection persist 20 for months Decline in SARS-CoV-2 Antibodies After Mild 22 Infection Among Frontline Health Care Personnel in a Multistate Hospital Network -12 States SARS-CoV-2 variant of concern 202012/01 (B.1.1.7): an exploratory analysis of a randomised 26 controlled trial